Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.225 (2.28%)
Spread: 0.80 (8.247%)
Open: 9.875
High: 10.10
Low: 9.875
Prev. Close: 9.875
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

Mon, 05th Feb 2024 14:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

ECR Minerals PLC - Australia-focused gold exploration company - Drills seven successful holes, and says there is evidence of anomalous gold with the best result being 23.39 grammes per tonne of gold over metre. Says the best sample still has 4.7 g/t of gold in the tailings of the initial results. Chief Executive Officer Mike Whitlow says: "This is an encouraging start to our examination of Davey Road. Based on ECR's work historically in this region, our expectation was that any gold would be both course and confined within narrow veins. These preliminary results support this assumption and consequently analysis of the bulk samples is a necessary step before we have a full picture of the geology. There is plenty so far to be pleased with but these results are indicative only and we look forward to gaining a better understanding of the location once full testing is complete."

----------

FireAngel Safety Technology Group PLC - Coventry, England-based developer and supplier of home safety products - Expects to report sales for 2023 of approximately GBP41.0 million, down 29% from GBP57.5 million a year ago. Says UK Trade division performance suffered from the restructuring in its sales team. International sales also remained comparatively depressed in the second half of 2023, it says, as new legislation in Benelux in 2022, which had led to a surge in customer demand in the region for products during 2022, was not carried into 2023 as customers looked to reduce inventory intake.At December 31, FireAngel had net debt of GBP3.1 million, down from GBP4.8 million in 2022.

----------

Smarttech247 Group PLC - Cork, Ireland-based artificial intelligence-enhanced cybersecurity services provider - Expands its NoPhish email security tool to Google Mail users. Says NoPhish employs advanced analysis algorithms to evaluate the content and legitimacy of the reported emails, offering instant feedback to the user. In cases where an email is identified as suspicious or malicious, NoPhish takes proactive measures by automatically removing the email from the user's inbox, thereby mitigating the risk of accidental exposure to harmful content. CEO Raluca Saceanu says: "We are delighted to bring NoPhish to Google Mail users. Our mission has always been to provide cutting-edge, user-friendly cybersecurity tools and by making NoPhish available on one of the world's most widely used email platforms, we are taking a significant step towards making the digital world safer for everyone. The integration signifies major advancement in email security, as Google Mail's extensive user base can now benefit from Smarttech247's phishing detection and response technology. This expansion is part of our ongoing efforts to adapt and evolve in the face of ever-changing cyber threats, ensuring users across various platforms can enjoy a safer email experience."

----------

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious diseases - Says Sally Adams resigns as chief development officer, while Callum Scott is named as the new head of development, effective immediately. Says Adams will remain with the company part time for six months to ensure a "smooth and effective transition of responsibilities."

According to Scancell, Scott has more than 15 years of experience in vaccine research and development. Previously, he held the role of technical transfer & formulation development manager at biotech firm Allergy Therapeutics PLC. CEO Lindy Durrant says: "Firstly, on behalf of the Scancell board, I would like to express our sincere gratitude to Sally for her expertise and support over the last 15 years, both on the board and leading clinical development. She has been instrumental in establishing a highly motivated development team and has worked tirelessly to bring our highly differentiated and valuable cancer vaccines through to the clinic. We wish her all the best for the future. "I would also like to warmly welcome Callum to Scancell. His understanding of the challenges involved in developing, registering, and commercialising novel biologics will be of great value to Scancell as we continue to develop our lead assets SCIB1 and Modi-1 through later stage clinical development."

----------

Alliance Pharma PLC - Chippenham, England-based distributor of consumer healthcare brands and prescription medicines - Appoints Camillo Pane as chair, effective February 19. He will be replacing Jo LeCouilliard. "Jo and the board feel that it is now appropriate for her to step down from the board and to appoint a new chair, with strong international consumer healthcare experience, to lead the company through its next strategic phase, focusing on organic growth through marketing and innovation," says Alliance Pharma. Senior Independent Director Richard Jones says: "On behalf of the Alliance board and the company I would like to thank Jo for her significant contribution to Alliance over the past five years and wish her well for the future. We look forward to Camillo joining the board as chair and harnessing his wide-ranging consumer healthcare experience to further enhance and develop our group strategy. In the meantime, the board remains focused on creating value for our shareholders by investing in growth whilst carefully managing our cost base."

----------

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
29 Aug 2023 14:27

Scancell appoints healthcare finance veteran as new CFO

(Sharecast News) - Immunotherapy developer Scancell announced the appointment of Sath Nirmalananthan as its new chief financial officer on Tuesday, effective immediately.

Read more
29 Aug 2023 09:53

IN BRIEF: Scancell appoints Prenetics' Sath Nirmalananthan as new CFO

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Hires Sath Nirmalananthan to be chief financial officer, starting immediately. Nirmalananthan previously was CFO for Europe, Middle East & Africa at Prenetics Ltd, a genomics-driven health sciences company. His appointment at Scancell follows Keith Green's retirement as director of finance.

Read more
31 Jul 2023 10:46

AIM WINNERS & LOSERS: Aptamer reshuffles board; Scancell expands trial

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
31 Jul 2023 10:23

Scancell shares jump on trial expansion for Modi-1 vaccine

(Alliance News) - Scancell Holdings PLC on Monday said it has expanded its Modi-1 trial for the use of checkpoint inhibitors on cancer patients.

Read more
10 Jul 2023 11:45

IN BRIEF: Scancell to focus on cancer vaccine assets amid trial data

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Will focus on lead cancer vaccine assets SCIB1 and Modi-1 following encouraging data from clinical trials. Adds phase two single arm scope trial investigating the safety and tolerability of using SCIB1 in combination with checkpoint inhibitors in patients with advanced melanoma is progressing well and notes a potential pathway for a registration trial. Adds it is fully funded to the second half of 2024 due to its increasing focus on the two clinical assets.

Read more
2 Jun 2023 13:18

Scancell to present positive recent findings at oncology summit

(Sharecast News) - Immunotherapy developer Scancell said on Friday that it is set to present an informative poster at the American Society of Clinical Oncology Meeting (ASCO) 2023 annual meeting in Chicago from 2 to 6 June.

Read more
13 Mar 2023 12:18

SUMMARY: London listings with exposure to Silicon Valley Bank

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
21 Feb 2023 12:14

Scancell shares jump on positive cancer vaccine progress

(Sharecast News) - Immunotherapy developer Scancell announced the completion of the monotherapy dose-finding arm of the phase 1 and 2 'ModiFY' clinical trial on Tuesday.

Read more
21 Feb 2023 11:56

Scancell shares up on encouraging data from ModiFY cancer trial

(Alliance News) - Scancell Holdings PLC on Tuesday said that it has completed the monotherapy dose finding arm of its multicentre Phase 1/2 ModiFY clinical trial, designed to treat cancer patients.

Read more
13 Feb 2023 11:38

Scancell gets positive result from needle-free Covid vaccines trial

(Alliance News) - Scancell Holdings PLC on Monday reported a positive response in its 'Covidity' trial, which aims to deliver needle-free injectable Covid vaccines.

Read more
1 Feb 2023 21:41

TRADING UPDATES: PetroNeft extends maturity; NetScientific loses chair

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
25 Jan 2023 14:43

TRADING UPDATES: Van Elle and Hargreaves Services post profit rises

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
18 Jan 2023 15:50

UK earnings, trading statements calendar - next 7 days

Thursday 19 January 
AJ Bell PLCTrading Statement
Bakkavor Group PLCTrading Statement
BHP Group LtdTrading Statement
boohoo Group PLCTrading Statement
Centamin PLCTrading Statement
Deliveroo PLCTrading Statement
Dunelm Group PLCTrading Statement
Energean PLCTrading Statement
Frontier Developments PLCHalf Year Results
Harbour Energy PLCTrading Statement
Headlam Group PLCTrading Statement
Ilika PLCHalf Year Results
Kier Group PLCTrading Statement
Luceco PLCTrading Statement
Network International Holdings PLCTrading Statement
Premier Foods PLCTrading Statement
Sage Group PLCTrading Statement
Zotefoams PLCTrading Statement
Friday 20 January 
4imprint Group PLCTrading Statement
Close Brothers Group PLCTrading Statement
Goldplat PLCFull Year Results
Ninety One PLCTrading Statement
Workspace Group PLCTrading Statement
PensionBee Group PLCTrading Statement
TheWorks.co.uk PLCHalf Year Results
Monday 23 January 
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Tuesday 24 January 
Accrol Group Holdings PLCHalf Year Results
Associated British Foods PLCTrading Statement
Henry Boot PLCTrading Statement
Oxford BioDynamics PLCFull Year Results
Saga PLCTrading Statement
Staffline Group PLCTrading Statement
Sureserve Group PLCFull Year Results
Velocity Composites PLCFull Year Results
Wednesday 25 January 
CMC Markets PLCTrading Statement
Conduit Holdings LtdTrading Statement
easyJet PLCTrading Statement
Forterra PLCTrading Statement
Hargreaves Services PLCHalf Year Results
hVIVO PLCTrading Statement
JD Wetherspoon PLCTrading Statement
Keywords Studios PLCTrading Statement
Quilter PLCTrading Statement
Scancell Holdings PLCHalf Year Results
Tullow Oil PLCTrading Statement
Van Elle Holdings PLCHalf Year Results
Watkin Jones PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
7 Nov 2022 12:56

Scancell in-licences SNAPvax technology for its Modi-2 cancer treatment

(Alliance News) - Scancell Holdings PLC on Monday said it has in-licensed SNAPvax technology from Vaccitech PLC to help develop its cancer treatments.

Read more
7 Nov 2022 09:29

Scancell licenses Vaccitech IP for its next vaccine candidate

(Sharecast News) - Scancell has in-licensed 'SNAPvax' technology from clinical-stage biopharmaceutical company Vaccitech, it announced on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.